A Multi-Level Trauma-Informed Approach to Increase HIV Pre-exposure Prophylaxis Initiation Among Black Women
MATCH
Trauma-Informed HIV Prevention for Black Women in Baltimore
2 other identifiers
interventional
300
1 country
1
Brief Summary
U.S. epidemiological data indicates that Black women are a high-risk HIV disparity group, yet initiation of novel prevention strategies like pre-exposure prophylaxis (PrEP) among this group is stagnant. Socio-structural challenges like intimate partner violence and gendered racism can constrain PrEP access among Black women, but few implementation studies have mitigated these challenges to improve PrEP initiation. The proposed research aims to implement and assess the effectiveness, implementation, and sustainability of a multilevel intervention to increase PrEP initiation among Black women with and without intimate partner violence in Baltimore.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2024
CompletedFirst Posted
Study publicly available on registry
November 25, 2024
CompletedStudy Start
First participant enrolled
February 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 1, 2028
March 23, 2026
March 1, 2026
2.8 years
November 7, 2024
March 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
PrEP initiation
Self-report of oral or injectable PrEP (Cabotegravir). Assessed from date of the most recent prescription.
Post baseline up to 6 months
Secondary Outcomes (1)
PrEP adherence
2-months post-randomization, 4-months post-randomization, and 6-months post-randomization
Study Arms (2)
Intervention Group (Peer Navigation)
EXPERIMENTALParticipants randomized to this arm will receive 4 weekly group sessions and 4 one-on-one sessions with a peer navigator
Control Group
PLACEBO COMPARATORParticipants randomized to this group will receive a single group session
Interventions
Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
Eligibility Criteria
You may qualify if:
- self-identified Black cisgender woman;
- self-reported HIV-negative status, and
- ≥18 years.
- reports unprotected vaginal or anal sex in the past 6 months with a male sexual partner,
- have at least one substantial HIV risk factor in the past 6 months according to the 2021 Centers for Disease Control (CDC) PrEP Eligibility Guidelines (i.e., HIV-positive sexual partner, recent bacterial Sexually Transmitted Disease (STD), 2+ sex partners, history of inconsistent or no condom use, commercial sex work, and residing in high HIV prevalence area or network), and
- never taken PrEP
You may not qualify if:
- non-English speaking and
- currently living with HIV
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Tiara C. Willie, PhD, MA
Johns Hopkins Bloomberg School of Public Health
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2024
First Posted
November 25, 2024
Study Start
February 28, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
February 1, 2028
Last Updated
March 23, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to privacy, confidentiality, and ethical considerations. Protecting personal information is essential to comply with privacy laws (e.g., HIPAA) and the terms of informed consent. Sharing such data could breach confidentiality agreements and potentially expose sensitive information, even if anonymized. Additionally, there are concerns about data security, misuse, and the potential harm to participants, which researchers must carefully consider.